TSC accompanying pulmonary lymphoma is a dubious disease in the area of the nervous system, clinical performance is complex and often involves multi-system fatigue. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment. Treatment and management of TSC accompanying pulmonary lymphoma requires individualized development, usually including multidimensional management of prognosis, including drug therapy, rehabilitation, regular follow-up, etc. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many formerly difficult-to-treat neurological disorders have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to the timely schedule according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of TSC-associated lymphocytic tumors. The platform serves a team of nationally and internationally authoritative experts in the field of neural systems related to the International Medical Service System of China, providing the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.